Van Nguyen-Tran

Van Nguyen-Tran

Auto-generated profile, based on publicly available information

Van Nguyen-Tran

The Scripps Institute, San Diego, CA USA

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2001 in Cell
Verified
Journal Article
Closed access
HKHai-Chien Kuo
Hai-Chien Kuo
Ching-Feng ChengChing-Feng Cheng
Ching-Feng Cheng
RCRobert B. Clark
Robert B. Clark
JLJim J.-C. Lin
Jim J.-C. Lin
JLJenny L.-C. Lin
Jenny L.-C. Lin
KCKenneth R. Chien
Kenneth R. Chien

26 October 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
WSWeijun Shen
Weijun Shen
BTBrandon Taylor
Brandon Taylor
QJQihui Jin
Qihui Jin
VNVan Nguyen-Tran
Van Nguyen-Tran
SMShelly Meeusen
Shelly Meeusen
BLBryan Laffitte
Bryan Laffitte
Insufficient pancreatic β-cell mass or function results in diabetes mellitus. While significant progress has been made in regulating insulin secretion from β-cells in diabetic patients, no pharmacological agents have been described that increase β-cell replication in humans. Here we report aminopyrazine compounds that stimulate robust β-cell proliferation in adult primary islets, most likely as a result of combined inhibition of DYRK1A and GSK3B. Aminopyrazine-treated human islets retain functionality in vitro and after transplantation into diabetic mice. Oral dosing of these compounds in diabetic mice induces β-cell proliferation, increases β-cell mass and insulin content, and improves glycaemic control. Biochemical, genetic and cell biology data point to Dyrk1a as the key molecular target. This study supports the feasibility of treating diabetes with an oral therapy to restore β-cell mass, and highlights a tractable pathway for future drug discovery efforts.

1 July 2009 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SKSandra Kleiner
Sandra Kleiner
VNVan Nguyen-Tran
Van Nguyen-Tran
OBOlivia Baré
Olivia Baré
XHXueming Huang
Xueming Huang
BSBruce Spiegelman
Bruce Spiegelman
ZWZhidan Wu
Zhidan Wu
PPARδ (peroxisome proliferator-activated receptor δ) is a regulator of lipid metabolism and has been shown to induce fatty acid oxidation (FAO). PPARδ transgenic and knock-out mice indicate an involvement of PPARδ in regulating mitochondrial biogenesis and oxidative capacity; however, the precise mechanisms by which PPARδ regulates these pathways in skeletal muscle remain unclear. In this study, we determined the effect of selective PPARδ agonism with the synthetic ligand, GW501516, on FAO and mitochondrial gene expression in vitro and in vivo. Our results show that activation of PPARδ by GW501516 led to a robust increase in mRNA levels of key lipid metabolism genes. Mitochondrial gene expression and function were not induced under the same conditions. Additionally, the activation of Pdk4 transcription by PPARδ was coactivated by PGC-1α. PGC-1α, but not PGC-1β, was essential for full activation of Cpt-1b and Pdk4 gene expression via PPARδ agonism. Furthermore, the induction of FAO by PPARδ agonism was completely abolished in the absence of both PGC-1α and PGC-1β. Conversely, PGC-1α-driven FAO was independent of PPARδ. Neither GW501516 treatment nor knockdown of PPARδ affects PGC-1α-induced mitochondrial gene expression in primary myotubes. These results demonstrate that pharmacological activation of PPARδ induces FAO via PGC-1α. However, PPARδ agonism does not induce mitochondrial gene expression and function. PGC-1α-induced FAO and mitochondrial biogenesis appear to be independent of PPARδ.

1 September 2000 in Cell
Verified
Journal Article
Closed access
VNVân T.B Nguyêñ-Trân
Vân T.B Nguyêñ-Trân
SKSteven W Kubalak
Steven W Kubalak
SMSusumu Minamisawa
Susumu Minamisawa
CFCéline Fiset
Céline Fiset
KWKai C Wollert
Kai C Wollert
KCKenneth R Chien
Kenneth R Chien

20 February 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YLYahu A. Liu
Yahu A. Liu
QJQihui Jin
Qihui Jin
YZYefen Zou
Yefen Zou
QDQiang Ding
Qiang Ding
SYShanshan Yan
Shanshan Yan
JLJon Loren
Jon Loren

1 July 1993 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
HZH Zhu
H Zhu
VNV T Nguyen
V T Nguyen
ABA B Brown
A B Brown
APA Pourhosseini
A Pourhosseini
AGA V Garcia
A V Garcia
KCK R Chien
K R Chien
The AT-rich element MEF-2 plays an important role in the maintenance of the muscle-specific expression of a number of cardiac and skeletal muscle genes. In the MLC-2 gene, an AT-rich element (HF-1b) which contains a consensus MEF-2 site is required for cardiac tissue-specific expression. The present study reports the isolation and characterization of a cDNA which encodes a novel C2H2 zinc finger (HF-1b) that binds in a sequence-specific manner to the HF-1b/MEF-2 site in the MLC-2 promoter. A number of independent criteria suggest that this HF-1b zinc finger protein is a component of the endogenous HF-1b/MEF-2 binding activity in cardiac muscle cells and that it can serve as a transcriptional activator of the MLC-2 promoter in transient assays. These studies suggest that, in addition to the previously reported RSRF proteins, structurally divergent transcriptional factors can bind to MEF-2-like sites in muscle promoters. These results underscore the complexity of the regulation of the muscle gene program via these AT-rich elements in cardiac and skeletal muscle.